Von Willebrand Disease

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

NCT00701545 | PHASE 2 | OBSERVATIONAL

As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective, multi-center structured data collection of routine management of patients with von Willebrand disease treated with Humate P® ivr in Canada. The surveillance will be non-interventional and non-experimental. During the observation period, the routine medical care of the patient will be documented. It is expected that there will be no difference in the safety and tolerability of Humate-P® ivr compared to Humate-P®

21 Participants

Recruiting

18 Years to 85 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Eligibility Criteria

Inclusion Criteria

* Male or female patients of any age;
* Patients who are suffering with von Willebrand disease previously treated with Humate-P®;
* Patients who are able to communicate well with the Investigator and his/her representatives;
* Patients who are able and agreeing to comply with all study requirements;
* Patients who have provided written signed and dated informed consent prior to any study procedures being performed.

Exclusion Criteria

* Patients who have received any investigational drug ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.

Additional Studies

Additional studies can be found at ClinicalTrials.gov